



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Saturday, January 10, 2009

Techniclone International Corporation

[View the current Techniclone International Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/10057-Techniclone+International+Corporation.html)

(<http://www.bioportfolio.com/bi corporate/10057-Techniclone+International+Corporation.html>)

Contact Details:

14282 Franklin Avenue

Tustin

CA

92680-7017

United States of America

Tel: 714 508 6000

Fax: 714 838 9433

Email:

TECHNICLONE CORPORATION is engaged in the research and development of unique therapeutics for the treatment of cancer: The company utilizes innovative targeting technologies to develop products capable of destroying cancerous tumors throughout the body. The Company's Tumor Necrosis Therapy (TNT) is designed to deliver high doses of radiation directly to the core of the tumor while causing minimal damage to surrounding tissue. Oncolym®, therapy for the treatment of advanced Non-Hodgkin's B-Cell Lymphoma. The Company is also developing two additional technologies for the treatment of solid tumors, Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA). VEAs act on tumors to increase the concentration of conventional chemotherapy in the tumor site while VTA's attach to tumor blood vessels creating a blood clot which kills the tumor by eliminating its oxygen and nutrient supply.

BioNews Results for Techniclone International Corporation



- [International Stem Cell Using New Funding to Retire Debt](#)
San Diego Business Journal: Jan 3 2009 4:00AM Matching: international
- [Investigators Find New Syndrome Linked to Congenital Neutropenia](#)
Genetic Engineering News: Jan 3 2009 10:47AM Matching: international
- [Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc](#)
MedIndia: Jan 3 2009 8:57AM Matching: international
- [Dancing TV host Lin spreads hope to cancer patients](#)
MyEGov Taiwan: Jan 3 2009 8:44AM Matching: international
- [Data on osteotomy discussed by researchers at Ibb University, Department of Orthodontics](#)
NewsRX: Jan 3 2009 2:16AM Matching: international
- [Highlights of the 8th International Conference on Pain and Chemical Dependency](#)
Abstracts in Hematology and Oncology: Jan 2 2009 6:19PM Matching: international
- [Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc](#)

- TradingMarkets: Jan 2 2009 1:44PM Matching: international*
- [Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc](#)
PR Newswire: Jan 2 2009 1:43PM Matching: international
 - [Interpreter Association IMIA Starts Campaign to Promote Code of Ethics for Medical Interpreters Worldwide](#)
Montana's News Station: Jan 2 2009 8:19PM Matching: international
 - [Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc](#)
KLFY: Jan 2 2009 4:29PM Matching: international
 - [Interpreter Association IMIA Starts Campaign to Promote Code of Ethics for Medical Interpreters Worldwide](#)
KLFY: Jan 2 2009 4:29PM Matching: international
 - [Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc](#)
Montana's News Station: Jan 2 2009 4:17PM Matching: international
 - [Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc](#)
Financials.com: Jan 2 2009 3:53PM Matching: international
 - [Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc](#)
KSLA: Jan 2 2009 3:04PM Matching: international
 - [Interpreter Association IMIA Starts Campaign to Promote Code of Ethics for Medical Interpreters Worldwide](#)
KSLA: Jan 2 2009 3:04PM Matching: international

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

